Mestranol/norethisterone
Not to be confused with Mestranol/noretynodrel.
Combination of | |
---|---|
Mestranol | Estrogen |
Norethisterone | Progestogen |
Clinical data | |
Trade names | Norethin, Noriday, Norinyl, Norquen, Ortho-Novum, others |
AHFS/Drugs.com | Monograph |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
Mestranol/norethisterone (brand names Norethin, Noriday, Norinyl, Norquen, Ortho-Novum, others) is a combination of the estrogen ethinylestradiol and the progestin norethisterone (norethindrone) which was introduced in 1963 and was the second combined oral contraceptive to be marketed, following mestranol/noretynodrel in 1960.[1] Although most mestranol-containing oral contraceptive formulations have been discontinued, the combination remains available today in the United States in a single formulation under the brand name Norinyl 1+50 28-Day.[2] It has largely been superseded by ethinylestradiol/norethisterone, which has been marketed under many of the same brand names.[3][4]
See also
References
- ↑ Marks L (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 74, 76. ISBN 978-0-300-16791-7.
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 22 December 2016.
- ↑ Blum RW (22 October 2013). Adolescent Health Care: Clinical Issues. Elsevier Science. pp. 216–. ISBN 978-1-4832-7738-7.
- ↑ Varney H, Kriebs JM, Gegor CL (2004). Varney's Midwifery. Jones & Bartlett Learning. pp. 515–. ISBN 978-0-7637-1856-5.
Comparison | |||||
---|---|---|---|---|---|
Behavioral |
| ||||
Barrier and / or spermicidal | |||||
Hormonal (formulations) |
| ||||
Anti-estrogen |
| ||||
Post-intercourse | |||||
Intrauterine device | |||||
Sterilization |
| ||||
Experimental | |||||
Long-acting reversible contraception (LARC) |
Androgens | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Estrogens | |||||||||||||
Progestogens |
|
Progesterone receptor modulators | |||||||
---|---|---|---|---|---|---|---|
PR |
| ||||||
mPR (PAQR) |
| ||||||
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.